AQST - Aquestive Therapeutics, Inc.
Aquestive Therapeutics, Inc. is a pharmaceutical company focused on discovering, developing, and commercializing products to address significant unmet medical needs across both the United States and international markets. The company's commercialized portfolio includes: Sympazan, an oral soluble film formulation of clobazam for individuals with Lennox-Gastaut syndrome.
As of Jun 30, 2026: spot at $4.17, ATM IV 46.6%, max pain $4.00, net GEX $81.3K.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Market Cap
- $436.0M
- Beta
- 1.45
- 52-Week Range
- 2.93-7.55
- CEO
- Daniel Barber
- Employees
- 142
- IPO Date
- Jul 25, 2018
- Exchange
- NASDAQ
What AQST Looks Like to Options Traders Today
IV rank of 6.7% is subdued relative to the 1-year history, conditions that typically favor premium-buying or long-volatility structures (debit spreads, calendar spreads, long straddles); positive net gamma exposure ($81.3K) means dealers hedge against trend, damping realized volatility and biasing price toward heavy-OI strikes; the 25-delta skew (0.246) prices calls richer than puts, often reflecting upside speculation or squeeze risk.
What This Page Covers
The AQST overview links into per-metric analysis views: max pain, gamma exposure, volatility skew, expected move, options chain, open interest history, and aggregate Greeks. Microstructure data is available on short interest, short volume, fail-to-deliver, and market structure. Corporate data is on fundamentals, earnings, analyst ratings, and insider trading.
Frequently asked AQST overview questions
- What is AQST?
- AQST is the ticker symbol for Aquestive Therapeutics, Inc., a listed security. Aquestive Therapeutics, Inc. is a pharmaceutical company focused on discovering, developing, and commercializing products to address significant unmet medical needs across both the United States and international markets. Listed on NASDAQ. AQST is the equity ticker shown on this page; equity options traders use the security for directional, volatility, and income strategies via the listed options chain.
- What does the AQST options snapshot look like today?
- As of Jun 30, 2026, the AQST options snapshot shows spot at $4.17, ATM IV 46.6%, IV rank 6.7%, max pain $4.00, net GEX $81.3K, expected move 13.36%. The full options chain, Greeks by strike and expiration, per-strike open-interest distribution, dealer gamma and delta exposure, and the volatility skew surface are linked from this overview page. Each per-metric route refreshes once per trading session and reflects the most recent close-of-business listed-options state.
- What are AQST's key statistics?
- Aquestive Therapeutics, Inc. (AQST) carries a market capitalization of $436.0M, beta of 1.45 relative to the broader market, 52-week range of 2.93-7.55. Full income statement, balance sheet, cash flow, and TTM ratio history is on the per-ticker fundamentals page; daily price history and 52-week levels are accessible from the same view. These structural inputs frame how the options market prices implied volatility around earnings windows and capital events.
- What sector or industry does AQST belong to?
- Aquestive Therapeutics, Inc. operates in the Healthcare sector, in the Drug Manufacturers - Specialty & Generic industry. Sector classification affects how the ticker correlates with sector ETFs, how it reacts to macro factors like rate moves and commodity prices, and how its options pricing compares to sector peers. Compare AQST's implied volatility and skew against sector benchmarks to gauge whether the options market is pricing single-name or systemic risk relative to the broader peer group.
- How current is the AQST data on this page?
- The options snapshot above is dated Jun 30, 2026 and refreshes once per session, with all per-strike Greeks and exposure aggregates recomputed at the daily close. Company-profile fields (sector, industry, market cap, P/E, IPO date) refresh from the vendor feed nightly. Financials and earnings refresh as 10-K and 10-Q filings are parsed (typically within several business days of the actual report). FINRA microstructure data refreshes on the source's cadence (daily for short volume, bi-monthly for short interest, weekly for the OTC volume file, twice-monthly for SEC FTD).